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Renal response to repeated 
exposure to endotoxin: 
Implications for acute kidney injury
KA Nath1
Zager and colleagues demonstrate that endotoxin tolerance is 
accompanied by an augmented inflammatory response in the kidney, 
the latter also exhibiting cholesterol-dependent cytoresistance. These 
novel findings are discussed mainly from the perspective of acute 
kidney injury and its prevention by preconditioning and the elicitation 
of cytoprotective pathways.
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As is the case for a number of syndromes 
in nephrology, the pathogenesis of clini-
cal acute kidney injury (AKI) is oft en 
multifactorial and may refl ect either the 
synergistic effects of different insults 
occurring and acting in concert, or 
the integrative eff ects of intermittently 
imposed insults. Insults that contrib-
ute to AKI are conventionally classifi ed 
as ischemic or nephrotoxic, and either 
of these insults is much more likely to 
cause AKI if accompanied by the other, 
or if imposed repeatedly on the kidney. 
Th at kidney function is oft en unaltered 
aft er an isolated episode of ischemia or 
a limited exposure to a given nephro-
toxin, bespeaks a certain innate capacity 
of the kidney to ward off  the perturbing 
eff ect of ischemic or nephrotoxic stress; 
this capacity may be overwhelmed, how-
ever, and renal function consequently 
impaired, if such insults are imposed 
simultaneously or serially on the kid-
ney. Understanding the nature of renal 
resistance to injury and the aggregative 
eff ects of insults on the kidney may thus 
provide fundamental insights regarding 
the pathogenesis of AKI.
Th ese issues have been explored and 
elucidated by Zager and colleagues for 
more than two decades, and their cur-
rent study1 (this issue) provides new and 
important insights regarding the systemic 
and renal responses to repeated admin-
istration of endotoxin (lipopolysaccha-
ride (LPS)). Endotoxin is relevant to AKI 
because of several considerations. Endo-
toxemia may contribute to AKI not only 
in overt sepsis but also in the systemic 
infl ammatory response syndrome, and, 
in either syndrome, AKI is a signifi cant 
determinant of morbidity and mortality. 
Additionally, ischemic and nephrotoxic 
AKI arises, at least in part, via diverse 
processes generically classifi ed under the 
rubric of infl ammation; LPS, the arche-
typal instigator of inflammation, thus 
exerts eff ects that are broadly relevant to 
AKI. Finally, LPS can induce other patho-
biologic eff ects relevant to AKI, including 
vasoconstriction and apoptosis.
To assess the systemic and renal eff ects 
of LPS, Zager and collaborators1 evalu-
ated a panel of infl ammation-relevant 
markers consisting of a T-helper 1 proin-
fl ammatory cytokine (tumor necrosis 
factor-α), a T-helper 2 anti-infl amma-
tory cytokine (interleukin-10), a chemo-
kine (monocyte chemotactic protein-1), 
and a proinfl ammatory signaling system 
(inducible nitric oxide synthase), all of 
which are incriminated in the patho-
genesis of AKI; tumor necrosis factor-α, 
monocyte chemotactic protein-1, and 
inducible nitric oxide synthase (iNOS) 
can promote AKI, whereas interleukin-
10 can protect against AKI. Th ese inves-
tigators noted that the systemic and renal 
responses to LPS were fundamentally 
altered in animals conditioned by prior 
exposure to LPS.1 LPS-treated mice, 
in response to a second dose of LPS, 
exhibited an attenuation in the systemic 
inflammatory response, a phenome-
non previously recognized and termed 
endotoxin tolerance. Remarkably, in 
this endotoxin-tolerant state, the renal 
response was quite the opposite, dis-
playing a heightened response charac-
terized by increased renal production of 
tumor necrosis factor-α, interleukin-10, 
and iNOS. To explore the basis for this 
heightened response to LPS, renal proxi-
mal tubules from LPS-conditioned mice 
were studied. Th ese tubules exhibited 
an intrinsic cytoresistance to hypoxia/
reoxygenation injury and insults induced 
by membrane destabilization; and 
such cytoresistance was dependent on 
increased amounts of cholesterol which 
accumulated in renal proximal tubules 
aft er the fi rst dose of LPS (Figure 1).
That renal injury induced by a given 
insult can be mitigated by prior exposure 
to another insult seems surprising, counter-
intuitive, and contrary to the more plau-
sible prediction that such insults would 
exacerbate renal injury. Yet such acquisi-
tion of resistance to injury has long been 
recognized in the kidney and other tis-
sues in experimental settings, and indeed, 
the existence of this phenomenon in the 
kidney was described a century ago.2 Th e 
blunted cytokine response that underlies 
endotoxin tolerance is a particular exam-
ple of acquired resistance to injury, as is 
ischemic preconditioning, wherein sus-
ceptibility to ischemic injury is reduced by 
a prior ischemic episode.3 Ischemic pre-
conditioning, documented experimentally 
in the heart and numerous other tissues, 
was fi rst described in the kidney by Zager 
and collaborators in 1984, and during their 
studies that defi ned the renal response to 
repeated episodes of ischemia.4 Although 
ischemic  preconditioning in the heart, 
liver, and other tissues occurs clinically, 
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it is currently uncertain whether humans, 
exposed to ischemic or nephrotoxic insults, 
become conditioned and protected against 
kidney injury. Unlike AKI, which calls 
attention to itself by a decrease in urinary 
output or a rise in blood urea nitrogen or 
serum creatinine, acquired renal resistance 
to injury is a silent, unobtrusive phenom-
enon in which renal function remains 
unimpaired or unaltered; acquired renal 
resistance probably occurs in humans 
but goes unnoticed because of this lack of 
change in kidney function. In this regard, 
the current fi ndings of Zager et al.1 sup-
port the likelihood that such resistance 
occurs in clinical settings. For example, 
although AKI is a common occurrence in 
patients in the intensive care setting, there 
are patients who experience episodes of 
sepsis or systemic infl ammatory response 
syndrome, transient hypotension, and 
exposure to contrast dye and other poten-
tial nephrotoxins, and yet in whom renal 
function is, surprisingly, well preserved. 
Th e present fi ndings raise the possibility 
that in such patients, a conditioning eff ect 
by exposure to LPS may confer resistance 
to other insults.
Another consideration germane to 
the clinical occurrence of acquired renal 
resistance is that in the experimental 
setting, specific conditions are often 
required for the phenomenon to occur. 
Th ese conditions involve the type, dura-
tion, and severity of each insult, and the 
interval between these insults; addition-
ally, cytoresistance is often exhibited 
within a defi ned time frame aft er the fi rst 
insult. Such specifi city may refl ect the 
conditions necessary to elicit the pivotal 
pathway or pathways precisely required 
for protection against the second insult 
and may account, for example, for resist-
ance to ischemic injury conferred by LPS 
as observed in some but not all studies.5
To determine the basis for the observed 
resistance to injury, Zager and collabo-
rators drew on their prior fi ndings dem-
onstrating that increased amounts of 
membrane cholesterol appear in the 
kidney injured by any one of a number 
of insults.6 Such accumulation of cho-
lesterol faithfully correlated with cytore-
sistance exhibited by the injured kidney; 
for example, assorted manipulations that 
decreased the amounts of cholesterol in 
the injured kidney concomitantly viti-
ated the cytoresistance that was other-
wise exhibited by the injured kidney. 
Th ese fi ndings led to the seminal thesis 
that increased amounts of cholesterol in 
the injured kidney conferred resistance 
to subsequent insults. Th e basis for this 
cytoprotective property of cholesterol was 
ascribed, quite plausibly, to the funda-
mental role of cholesterol in maintaining 
the integrity of cell membranes, the latter 
representing a critical determinant of cel-
lular vitality and a provenance for myriad 
cell signaling pathways and other cellu-
lar processes. Remarkably, in the current 
study,1 the resistance exhibited by LPS-
conditioned renal tubules refl ected and 
required increased cholesterol content 
induced by LPS.
Increased cholesterol content also 
correlated with, and contributed to, 
the augmented infl ammatory response 
observed in the kidney in response to 
the second dose of LPS. It is intrigu-
ing that a cytoresistant state evinces 
a heightened inflammatory response 
to LPS, and as Zager et al. point out, 
such a coexistence of fi ndings has been 
observed in their prior studies.1 Aspects 
of an infl ammatory response may be rel-
evant to cytoprotection. For example, in 
LPS-conditioned tubules, expression of 
interleukin-10, a cytoprotective gene,7 
is induced. The increased expression 
of iNOS in LPS-conditioned tubules 
is also pertinent. Studies by Bonventre 
and collaborators confi rmed the exist-
ence of ischemic preconditioning in the 
kidney and demonstrated that this phe-
nomenon, at least in part, is accounted 
for by increased expression of iNOS.8 
Interestingly, iNOS is also recognized 
as a signifi cant contributor to ischemic 
AKI,9 and this ironic duality of eff ects 
— iNOS as a cause of acute AKI and a 
determinant of ischemic precondition-
ing — underscores the context specifi city 
of substances incriminated in acquired 
resistance to injury. Indeed, cholesterol 
can confer cytoresistance in the injured 
kidney but can drive atherogenesis in the 
injured vasculature.
AKI and strategies that can protect 
against it may be viewed from a perspec-
tive provided by Th e Tipping Point. In Th e 
Tipping Point, Gladwell illustrates how 
the confl uence of seemingly unimpor-
tant but interacting events can instigate, 
at a critical and defi ning moment, the 
emergence of important and irrevocable 
phenomena.10 In the acutely ill patient, 
the integrative eff ects of ischemic and/or 
nephrotoxic insults may induce a tipping 
point in the kidney such that AKI ine-
luctably emerges. Novel biomarkers may 
forecast the approach of such a tipping 
point, and current and creative strategies 
may prevent their occurrence. Current 
preventive approaches seek to mini-
mize the risk of exposure to ischemic 
and nephrotoxic stress; novel preven-
tive strategies may seek to recruit and 
use renal cytoprotective responses that 
oppose the tipping of the stressed kidney 
into AKI. Th e novel demonstration that 
cholesterol-dependent protection can be 
Figure 1 | Schematic drawing depicting the experimental approach and salient findings. 
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induced by a potentially toxic substance 
such as LPS, and even in the setting of 
heightened renal infl ammation, under-
scores the appeal of preconditioning and 
the recruitment of cytoprotective path-
ways as strategies to prevent AKI.
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Renal albumin handling: A look at 
the dark side of the filter
M Gekle1
Renal albumin handling is of major interest because albuminuria 
is an important risk factor for reno-cardiovascular diseases. In this 
issue a challenging study attempts to shift the paradigm of very low 
fractional albumin filtration and degradation in proximal tubule 
cells. The conclusions are of great potential relevance but require 
urgent validation so that we gain a clearer view of the dark side of the 
glomerular filter. 
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Renal protein handling, especially renal 
albumin handling, attracts increasing 
interest in basic renal research and gains 
growing importance in clinical nephrol-
ogy as well as cardiovascular medicine. 
First we have the basic desire to under-
stand the kidneys’ function as well as 
possible mechanisms leading to dysfunc-
tion, such as proteinuria. Furthermore, 
the excretion of albumin with the fi nal 
urine (albuminuria) is being recognized 
as a major risk factor for renal and car-
diovascular diseases. Although there is a 
clear epidemiological correlation, there 
is no rational explanation of the causa-
tive links.1,2 Recently, pressure-induced 
and mineralocorticoid receptor-medi-
ated damage of podocytes has been sug-
gested as a link between albuminuria and 
risk of cardiovascular diseases.3 Finally, 
the protein load in the proximal tubular 
lumen has been recognized as an impor-
tant parameter for the development of 
tubulointerstitial diseases and ultimately 
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for the progression of renal-function 
decline.1,4 Albuminuria, therefore, is 
marker and motor of renal and cardio-
vascular diseases.
As for every plasma constituent enter-
ing the kidneys, the basic equation 
arterial input = venous output + urine 
output + metabolism
holds true for serum albumin. How-
ever, this equation treats the kidney as a 
black box and neglects the crucial intrare-
nal mechanisms leading to urine forma-
tion and metabolism. Urine output results 
from fi ltration + secretion – reabsorption. 
Th us the complete equation is
arterial input = venous output + (fi ltra-
tion + secretion – reabsorption) + metab-
olism.
In order to understand the fate of any 
substance in the kidney we have to know 
its behavior with respect to filtration, 
secretion, and reabsorption. For serum 
albumin there is consensus that no rel-
evant secretion occurs. Th us, we have to 
understand fi ltration and reabsorption 
of albumin.
Th e composition of glomerular ultrafi l-
trate depends on the permeability proper-
ties of the glomerular fi lter barrier, which 
is negatively charged and has pores with 
a theoretical mean diameter of about 
4 nm.1 Th us, under physiological condi-
tions molecules with eff ective diameters 
greater than 4 nm are not freely fi ltered 
but are retained to an increasing extent 
as the diameter increases, that is, as the 
fractional fi ltration (= substrate concen-
tration in renal ultrafi ltrate / substrate 
concentration in plasma) decreases from 
1 to 0. Furthermore, negatively charged 
macromolecules with eff ective diameters 
close to the fi lter pore diameter seem to be 
restricted to a greater extent as compared 
with neutral molecules of comparable 
size. For a freely fi ltered substance, such 
as glucose, the fi ltered amount can be eas-
ily determined as the product of glomeru-
lar fi ltration rate × plasma concentration. 
For albumin the eff ective radius is in the 
range of 7.5 nm,5 resulting in a fractional 
fi ltration <<1, (Figure 1) which has been 
previously assumed to range between 
0.0005 and 0.0007.1,6 Further calculations 
suggested that fractional fi ltration may be 
